APA (7th ed.) Citation

Qi, L., Shen, H., Chai, M., Chen, B., He, Y., Shi, X., . . . Huo, Y. (2025). Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: A post-hoc analysis of pooled data from three phase 3 trials. Cardiovascular Diabetology, 24(1), 1. https://doi.org/10.1186/s12933-025-02816-3

Chicago Style (17th ed.) Citation

Qi, Litong, et al. "Efficacy and Safety of Tafolecimab in Chinese Patients with Type 2 Diabetes and Hypercholesterolemia: A Post-hoc Analysis of Pooled Data from Three Phase 3 Trials." Cardiovascular Diabetology 24, no. 1 (2025): 1. https://doi.org/10.1186/s12933-025-02816-3.

MLA (9th ed.) Citation

Qi, Litong, et al. "Efficacy and Safety of Tafolecimab in Chinese Patients with Type 2 Diabetes and Hypercholesterolemia: A Post-hoc Analysis of Pooled Data from Three Phase 3 Trials." Cardiovascular Diabetology, vol. 24, no. 1, 2025, p. 1, https://doi.org/10.1186/s12933-025-02816-3.